CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT

ANG LIFESCIENCES
INDIA LIMITED

Ref. No. ANGI/26-27/246

Date. 14-11-26

To

Department of Corporate Services
BSE Limited
P J Tower, Dalal Street
Mumbai-400001

Ref: - BSE Security Code: 540694

Sub – Outcome of Board Meeting held on Saturday 14.11.2026 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is to inform you that pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), the Board of Directors of the Company, at its meeting held today, i.e., Saturday, November 14, 2026, inter alia, considered and approved the following matters:

(1) Unaudited financial result (standalone and consolidated) as per India Accounting Standards for the quarter & half year ended 30th September 2026; and
(2) Limited review report (standalone and consolidated) by M/s Khurana Sharma & Co.., Statutory Auditor of the Company.
(3) On the recommendation of Nomination & Remuneration Committee, the Board of Directors took note on the appointment of Mrs. Preeti Sarin (DIN: 11995485) as Additional Independent Director of the Company who shall hold office for a period of five (5) consecutive years with effect from 14th November, 2026 to 13th November, 2031(both days inclusive) subject to approval of the shareholders of the Company.

We hereby confirm that Mrs. Preeti Sarin satisfies the criteria of independence prescribed under the Companies Act, 2013 and SEBI Listing Regulations and that she is not debarred from holding the office of Director by virtue of any order passed by SEBI or any other such authority.

The disclosure as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is enclosed herewith as **Annexure A.**

The Board meeting was commenced at 05:00 pm and concluded at 09:15 PM.

Kindly take the same on your record.
Yours faithfully,
For ANG Lifesciences India Limited

Rajesh Gupta
Managing Director
DIN: 01423407

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT

ANG LIFESCIENCES
INDIA LIMITED

Ref. No. .....

Date.....

Annexure A

The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with circular No. SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Sr. No	Particulars	Mrs. Preeti Sarin
1.	Reason for change viz. appointment~~/reappointment, resignation, removal, death or otherwise.~~	Mrs. Preeti Sarin has been appointed as Additional Independent Director of the Company
2.	Date & Term of Appointment/~~Cessation~~ (as applicable)	14th November, 2026 For a term of 5 years from November 14, 2026, to November 13, 2031 subject to approval of Shareholders of the Company
3.	Brief Profile (in case of Appointment/~~Reappointment~~)	Mrs. Preeti Sarin is a qualified professional with a Bachelor of Business Administration (BBA) degree and over 10 years of professional experience. She has a strong understanding of business administration, management, operational coordination and organizational activities. She possesses good communication, leadership and interpersonal skills, along with experience in planning, coordination and handling administrative responsibilities. Her professional approach and business understanding enable her to contribute effectively to organizational growth and management.
4.	Disclosure of relationships between Directors(in case of appointment a Director	Mrs. Preeti Sarin is not related to any Director of the Company.
5.	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19	Mrs. Preeti Sarin is not debarred from holding the office of Independent Director by virtue of any SEBI order or any such authority.

For ANG Lifesciences India Limited

Rajesh Gupta
Managing Director
DIN: 01423407

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT

ANG LIFESCIENCES
INDIA LIMITED

Ref. No. ..... Date .....

Standalone Statement of Assets and Liabilities (₹ in lacs)

Particulars	As at 30 September 2026 (Unaudited)	As at 31 March 2026 (Audited)
A. Assets		
1. Non-current assets		
(a) Property, plant and equipment	4,303.09	4,547.24
(b) Right of use assets	114.30	158.25
(c) Financial assets		
i) Investments	352.00	352.00
ii) Other financial assets	19.90	19.38
(d) Deferred tax asset (net)	345.08	164.88
(c) Other non-current assets	29.03	29.03
Total non-current assets	**5,163.40**	**5,270.78**
2. Current assets		
(a) Inventories	3,926.28	3,300.14
(b) Financial assets		
i) Trade receivables	5,710.37	6,535.05
ii) Cash and cash equivalents	40.91	28.30
iii) Other bank balances	336.33	329.25
v) Other financial assets	409.22	415.16
(c) Other current assets	3,214.46	2,688.76
Total current assets	**13,637.56**	**13,296.66**
Assets held for sale	423.72	423.72
Total assets	**19,224.68**	**18,991.16**
B. Equity and liabilities		
Equity		
(a) Equity share capital	1,305.83	1,305.83
(b) Other equity	4,314.73	4,915.85
Total equity	**5,620.56**	**6,221.68**
Liabilities		
1. Non-current liabilities		
(a) Financial liabilities		
i) Borrowings	70.95	84.46
ii) Lease liabilities	34.24	99.85
iii) Other financial liabilities	9.50	9.50
(b) Provisions	124.60	117.94
Total non-current liabilities	**239.29**	**311.75**
2. Current liabilities		
(a) Financial liabilities		
i) Borrowings	7,087.03	6,412.52
ii) Lease liabilities	104.03	87.10
ii) Trade payables		
-Total outstanding dues of micro enterprises and small enterprises	1,041.78	1,858.26
-Total oustanding dues of creditors other than micro enterprises and small	3,409.57	2,140.63
iii) Other financial liabilities	362.20	351.17
(b) Other current liabilities	1,333.53	1,581.37
(c) Provisions	24.04	24.04
(d) Current tax liabilities (net)	2.64	2.64
Total current liabilities	**13,364.82**	**12,457.73**
Total equity and liabilities	**19,224.68**	**18,991.16**

Regd. Office: SCO-113, DARBARA COMPLEX, First Floor, B-BLOCK, Ranjit Avenue, Amritsar-143001.
Works: (UNIT-I) Village kishanpura, P.O: Manpura Nalagarh Road, Tehsil: Baddi, Distt.: Solan (HP)-174101
Works: (UNIT-IV) Kh. No. 139/2, Village Jodhapur, Barotiwala, Baddi Tehsil Nalagarh Distt.: Solan (HP)-174103
Works: (UNIT-V) Village Malkumajra, Nalagarh Road, Baddi Tehsil Nalagarh Distt.: Solan (HP)-173205
Ph. 0183-513345, 5133458. **Email:** operations@anglifesciences.com, **Website:** www.anglifesciences.com

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT

ANG LIFESCIENCES INDIA LIMITED

Ref. No. .....

Date.....

Statement of standalone unaudited results for the quarter and six months ended 30 September 2026

(₹ in lakhs except per share data)

	Particulars	Quarter ended 30 September 2026 (Unaudited)	Quarter ended 30 June 2026 (Unaudited)	Quarter ended 30 September 2025 (Unaudited)	Six months ended 30 September 2026 (Unaudited)	Six months ended 30 September 2025 (Unaudited)	Year ended 31 March 2026 (Audited)
I	Revenue from operations	1,857.59	1,395.79	2,597.05	3,253.38	5,050.23	9,160.45
II	Other income	19.59	19.26	20.78	38.85	38.12	72.66
III	**Total revenue (I+II)**	**1,877.18**	**1,415.05**	**2,617.83**	**3,292.23**	**5,088.35**	**9,233.11**
IV	**Expenses**						
	Cost of materials consumed	1,131.67	857.50	1,700.99	1,989.17	3,345.89	5,507.58
	Changes in inventories of finished goods and work-in-progress	91.98	77.77	(56.85)	169.75	(82.15)	321.04
	Employee benefits expense	336.22	346.92	386.35	683.14	735.78	1,434.64
	Finance costs	168.22	177.13	158.73	345.35	319.35	644.84
	Depreciation and amortisation expenses	148.07	146.89	145.38	294.96	290.00	608.18
	Other expenses	340.16	259.96	344.91	600.12	643.83	1,235.93
	Total expenses (IV)	**2,216.32**	**1,866.17**	**2,679.51**	**4,082.49**	**5,252.70**	**9,752.21**
V	**Loss before exceptional items and tax (III-IV)**	**(339.14)**	**(451.12)**	**(61.68)**	**(790.26)**	**(164.35)**	**(519.10)**
VI	Exceptional items	-	-	-	-	-	-
VII	**Loss before tax (V-VI)**	**(339.14)**	**(451.12)**	**(61.68)**	**(790.26)**	**(164.35)**	**(519.10)**
	Tax expense						
	(1) Current tax	-	-	-	-	-	-
	(2) Deferred tax	(73.08)	(109.36)	18.31	(182.44)	(5.63)	(46.45)
VIII	**Total tax expense (1+2)**	**(73.08)**	**(109.36)**	**18.31**	**(182.44)**	**(5.63)**	**(46.45)**
IX	**Loss for the period (VII-VIII)**	**(266.05)**	**(341.76)**	**(79.99)**	**(607.82)**	**(158.72)**	**(472.65)**
X	Other comprehensive income:						
	Items that will not be reclassified to profit or (loss)	4.49	4.48	2.63	8.97	5.26	17.94
	Income tax relating to items that will not be reclassified to profit or loss	(1.13)	(1.13)	(0.66)	(2.26)	(1.32)	(4.51)
XI	**Total comprehensive loss (IX+X)**	**(262.69)**	**(338.41)**	**(78.02)**	**(601.11)**	**(154.78)**	**(459.22)**
XII	Paid-up equity share capital (Face value ₹ 10/- per share)	1,305.83	1,305.83	1,305.83	1,305.83	1,305.83	1,305.83
XIII	Other equity						4,915.85
XIV	Earnings per equity share (of ₹ 10/- each)						
	- Basic and Diluted	(2.01)	(2.59)	(0.60)	(4.60)	(1.19)	(3.52)

See accompanying notes to the financial results.

Regd. Office: SCO-113, DARBARA COMPLEX, First Floor, B-BLOCK, Ranjit Avenue, Amritsar-143001.
Works: (UNIT-I) Village kishanpura, P.O: Manpura Nalagarh Road, Tehsil: Baddi, Distt.: Solan (HP)-174101
Works: (UNIT-IV) Kh. No. 139/2, Village Jodhapur, Barotiwala, Baddi Tehsil Nalagarh Distt.: Solan (HP)-174103
Works: (UNIT-V) Village Malkumajra, Nalagarh Road, Baddi Tehsil Nalagarh Distt.: Solan (HP)-173205
Ph. 0183-513345, 5133458. **Email:** operations@anglifesciences.com, **Website:** www.anglifesciences.com

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT

ANG LIFESCIENCES INDIA LIMITED

Ref. No. .....

Date.....

Standalone Cash Flow Statement		(₹ in lacs)
	Six months ended 30 September 2026 (Unaudited)	Six months ended 30 September 2025 (Unaudited)
A. CASH FLOW FROM OPERATING ACTIVITIES		
Loss before tax	**(790.26)**	**(164.35)**
Adjustment for:		
Depreciation and amortization expense	294.96	290.00
Bad debts written off	2.79	2.00
Provision for expected credit loss	9.93	22.78
Finance cost	345.35	319.35
Interest income	(28.23)	(29.07)
Operating profit before working capital changes	**(165.46)**	**440.71**
Adjustments for movement in:		
Inventories	(626.14)	224.90
Trade receivables	811.96	(2,118.15)
Other financial assets	5.43	(5.57)
Other assets	(525.70)	50.33
Other financial liabilities	12.28	(328.87)
Provisions	15.62	18.77
Trade payables	452.46	1,023.89
Other liabilities	(247.84)	232.23
Cash used in operations	**(267.39)**	**(461.76)**
Income taxes paid	(0.00)	(0.76)
Net cash flow used in operating activities	**(267.39)**	**(462.52)**
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of property, plant and equipment	(8.12)	(5.48)
Movement in fixed deposits	(7.08)	2.84
Interest received	28.23	29.07
Net cash flow generated from investing activities	**13.03**	**26.43**
C. CASH FLOW FROM FINANCING ACTIVITIES		
Movement in short term borrowings (net)	674.51	1,804.72
Movement in long term borrowings (net)	(13.51)	(1,006.31)
Interest paid	(337.48)	(306.86)
Payment of lease liabilities	(56.55)	(56.55)
Net cash flow used in financing activities	**266.97**	**435.00**
Net Increase/(decrease) in cash and cash equivalents	12.61	(1.09)
Cash and cash equivalents at the beginning of the year	28.30	7.91
Cash and cash equivalents at the end of the year	**40.91**	**6.82**
Notes:		
Cash and cash equivalents include:		
Cash on hand	40.77	6.68
Balances with banks on current accounts	0.14	0.14
	40.91	**6.82**

Regd. Office: SCO-113, DARBARA COMPLEX, First Floor, B-BLOCK, Ranjit Avenue, Amritsar-143001.
Works: (UNIT-I) Village kishanpura, P.O: Manpura Nalagarh Road, Tehsil: Baddi, Distt.: Solan (HP)-174101
Works: (UNIT-IV) Kh. No. 139/2, Village Jodhapur, Barotiwala, Baddi Tehsil Nalagarh Distt.: Solan (HP)-174103
Works: (UNIT-V) Village Malkumajra, Nalagarh Road, Baddi Tehsil Nalagarh Distt.: Solan (HP)-173205
Ph. 0183-513345, 5133458. **Email:** operations@anglifesciences.com, **Website:** www.anglifesciences.com

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT

ANG LIFESCIENCES INDIA LIMITED

Ref. No. .....

Date.....

Consolidated Statement of Assets and Liabilities (₹ in lacs)

Particulars	As at 30 September 2026 (Unaudited)	As at 31 March 2026 (Audited)
A. Assets		
1. Non-current assets		
(a) Property, plant and equipment	4,645.25	4,903.03
(b) Right-of-use assets	114.30	158.25
(c) Financial assets		
(i) Investments	2.57	2.57
(ii) Other financial assets	22.32	21.80
d) Income tax asset (net)	18.01	17.41
(e) Deferred tax asset (net)	1,125.43	827.38
(f) Other non-current assets	29.03	29.03
Total non-current assets	5,956.91	5,959.48
2. Current assets		
(a) Inventories	5,213.41	4,626.13
(b) Financial assets		
(i) Trade receivables	6,141.43	6,793.09
(ii) Cash and cash equivalents	73.78	49.39
iii) Other bank balances	336.64	329.55
iv) Other financial assets	406.50	419.08
(c) Other current assets	3,103.89	2,294.44
(d) Current tax assets	-	-
Total current assets	15,275.65	14,511.68
Assest held for sale	423.72	423.72
Total assets	21,656.28	20,894.88
B. Equity and liabilities		
Equity		
(a) Equity share capital	1,305.83	1,305.83
(b) Other equity	3,346.02	3,983.11
Total equity	4,651.85	5,288.94
Liabilities		
1. Non-current liabilities		
(a) Financial liabilities		
(i) Borrowings	350.99	461.63
(ii) Lease liabilities	34.24	99.85
(iii) Trade payables	-	-
(iv) Other financial liabilities	9.50	9.50
(b) Deferred tax liabilities (net)	-	-
(c) Provisions	138.97	131.28
Total non-current liabilities	533.70	702.26
2. Current liabilities		
(a) Financial liabilities		
(i) Borrowings	8,146.03	7,291.31
(ii) Lease liabilities	104.03	87.10
(iii) Trade payables		
-Total outstanding dues of micro enterprises and small enterprises	1,746.27	2,256.95
-Total oustanding dues of creditors other than micro enterprises and small e	4,366.32	2,993.94
(iv) Other financial liabilities	424.49	403.75
(b) Other current liabilities	1,654.57	1,841.53
(c) Provisions	26.39	26.46
(d) Current tax liabilities (net)	2.64	2.64
Total current liabilities	16,470.73	14,903.68
Total equity and liabilities	21,656.28	20,894.88

Regd. Office: SCO-113, DARBARA COMPLEX, First Floor, B-BLOCK, Ranjit Avenue, Amritsar-143001.
Works: (UNIT-I) Village kishanpura, P.O: Manpura Nalagarh Road, Tehsil: Baddi, Distt.: Solan (HP)-174101
Works: (UNIT-IV) Kh. No. 139/2, Village Jodhapur, Barotiwala, Baddi Tehsil Nalagarh Distt.: Solan (HP)-174103
Works: (UNIT-V) Village Malkumajra, Nalagarh Road, Baddi Tehsil Nalagarh Distt.: Solan (HP)-173205
Ph. 0183-513345, 5133458. **Email:** operations@anglifesciences.com, **Website:** www.anglifesciences.com

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT

ANG LIFESCIENCES
INDIA LIMITED

Ref. No. .....

Date.....

Statement of consolidated unaudited results for the quarter and six months ended 30 Sep 2026

(₹ in lakhs except per share data)

	Particulars	Quarter ended 30 September 2026 (Unaudited)	Quarter ended 30 June 2026 (Unaudited)	Quarter ended 30 September 2025 (Unaudited)	Six months ended 30 September 2026	Six months ended 30 September 2025	Year ended 31 March 2026 (Audited)
I	Revenue from operations	2,010.03	1,529.77	2,605.37	3,539.80	5,065.73	9,289.28
II	Other income	10.91	10.76	12.25	21.67	21.15	54.40
III	**Total revenue (I+II)**	**2,020.93**	**1,540.54**	**2,617.62**	**3,561.46**	**5,086.88**	**9,343.68**
IV	Expenses						
	Cost of materials consumed	1,188.42	965.13	1,805.12	2,153.55	3,447.88	5,733.77
	Changes in inventories of finished goods and work-in-progress	108.32	76.96	(20.93)	185.28	(41.35)	320.28
	Employee benefits expense	378.81	392.82	431.91	771.63	868.22	1,653.91
	Finance costs	207.73	223.51	189.35	431.24	383.04	793.42
	Depreciation and amortisation expenses	151.38	149.91	152.30	301.29	305.08	632.73
	Other expenses	360.84	290.16	381.29	651.00	718.55	1,510.64
	Total expenses (IV)	**2,395.50**	**2,098.49**	**2,939.04**	**4,493.99**	**5,681.42**	**10,644.75**
V	**Loss before exceptional items and tax (III-IV)**	**(374.57)**	**(557.95)**	**(321.41)**	**(932.52)**	**(594.53)**	**(1,301.06)**
VI	Exceptional items	-	-	-	-	-	-
VII	Loss before tax (V-VI)	(374.57)	(557.95)	(321.41)	(932.52)	(594.53)	(1,301.06)
	Tax expense						
	(1) Current tax	-	-	-	-	-	-
	(2) Deferred tax	(165.72)	(133.53)	(26.68)	-299.25	(99.18)	(192.59)
VIII	**Total tax expense (1+2)**	**(165.72)**	**(133.53)**	**(26.68)**	**(299.25)**	**(99.18)**	**(192.59)**
IX	**Loss for the period (VII-VIII)**	**(208.85)**	**(424.42)**	**(294.73)**	**(633.27)**	**(495.35)**	**(1,108.48)**
X	Other comprehensive income:						
	Items that will not be reclassified to profit or (loss)	2.38	2.37	2.63	4.75	5.26	9.49
	Income tax relating to items that will not be reclassified to profit or loss	(0.59)	(0.60)	(0.66)	(1.19)	(1.32)	(2.39)
XI	**Total comprehensive income (IX+X)**	**(207.07)**	**(422.65)**	**(292.77)**	**(629.72)**	**(491.41)**	**(1,101.37)**
XII	Paid-up equity share capital (Face value ₹ 10/- per share)	1,305.83	1,305.83	1,305.83	1,305.83	1,305.83	1,305.83
XIII	Other equity						
XIV	Earnings per equity share (of ₹ 10/- each)						
	a) Basic	(1.59)	(3.24)	(2.24)	(4.82)	(3.76)	(8.43)
	b) Diluted	(1.59)	(3.24)	(2.24)	(4.82)	(3.76)	(8.43)

See accompanying notes to the financial results.

Regd. Office: SCO-113, DARBARA COMPLEX, First Floor, B-BLOCK, Ranjit Avenue, Amritsar-143001.
Works: (UNIT-I) Village kishanpura, P.O: Manpura Nalagarh Road, Tehsil: Baddi, Distt.: Solan (HP)-174101
Works: (UNIT-IV) Kh. No. 139/2, Village Jodhapur, Barotiwala, Baddi Tehsil Nalagarh Distt.: Solan (HP)-174103
Works: (UNIT-V) Village Malkumajra, Nalagarh Road, Baddi Tehsil Nalagarh Distt.: Solan (HP)-173205
Ph. 0183-513345, 5133458. **Email:** operations@anglifesciences.com, **Website:** www.anglifesciences.com

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT

ANG LIFESCIENCES
INDIA LIMITED

Ref. No. .....

Date.....

Consolidated Cash Flow Statement		(₹ in lacs)
	Six months ended 30 September 2026	Six months ended 30 September 2025
A. CASH FLOW FROM OPERATING ACTIVITIES		
Loss before tax	**(932.53)**	**(594.53)**
Adjustment for:		
Depreciation and amortization expense	301.29	305.08
Bad debts written off	2.79	2.00
Provision for expected credit loss	9.93	22.78
Finance cost	431.24	383.04
Interest income	(17.59)	(17.91)
Loss on sale of property, plant and equipment	-	1.22
Operating profit before working capital changes	**(204.87)**	**101.68**
Adjustments for movement in:		
Inventories	(587.28)	350.27
Trade receivables	638.95	(1,582.94)
Other financial assets	12.05	17.06
Other assets	(809.22)	66.69
Other financial liabilities	20.74	(373.61)
Provisions	4.07	20.49
Trade payable	861.70	808.61
Other liabilities	(186.96)	250.72
Cash generated from operations	**(250.82)**	**(341.02)**
Income taxes paid	0.59	(0.84)
Net cash flow generated from operating activities	**(250.23)**	**(341.87)**
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of property, plant and equipment	(0.03)	(5.47)
Proceeds from sale of property, plant and equipment	-	40.00
Movement in fixed deposits	(7.09)	2.83
Interest received	17.59	17.91
Net cash flow used in investing activities	**10.47**	**55.27**
C. CASH FLOW FROM FINANCING ACTIVITIES		
Movement in long term borrowings (net)	588.95	(697.02)
Movement in short term borrowings (net)	155.14	1,407.88
Interest paid	(423.37)	(370.55)
Payment of lease liabilities	(56.55)	(56.55)
Net cash flow used in financing activities	**264.17**	**283.76**
Net Increase/(decrease) in cash and cash equivalents	24.41	(2.84)
Cash and cash equivalents at the beginning of the year	49.39	15.73
Cash and cash equivalents at the end of the year	**73.80**	**12.89**
Notes:		
Cash and cash equivalents include:		
Cash on hand	73.15	12.50
Balances with banks on current accounts	0.64	0.39
	73.79	12.89

Regd. Office: SCO-113, DARBARA COMPLEX, First Floor, B-BLOCK, Ranjit Avenue, Amritsar-143001.
Works: (UNIT-I) Village kishanpura, P.O: Manpura Nalagarh Road, Tehsil: Baddi, Distt.: Solan (HP)-174101
Works: (UNIT-IV) Kh. No. 139/2, Village Jodhapur, Barotiwala, Baddi Tehsil Nalagarh Distt.: Solan (HP)-174103
Works: (UNIT-V) Village Malkumajra, Nalagarh Road, Baddi Tehsil Nalagarh Distt.: Solan (HP)-173205
Ph. 0183-513345, 5133458. **E mail:** operations@anglifesciences.com, **Website:** www.anglifesciences.com

ANG LIFESCIENCES
INDIA LIMITED

Ref. No. .....

Date .....

As per Ind-AS 108, Operating Segments have been defined and presented based on the regular review by the Company's Chief Operating Decision Maker to assess the performance of each segment and to make decision about allocation of resources. The accounting principles used in the preparation of the consolidated unaudited financial results are consistently applied to record revenue and expenditure in individual segments. Accordingly, the consolidated unaudited segment wise revenue, results, assets, and liabilities is as follows :

S.No.	Particulars	Quarter ended			Six months ended		Year ended
		30 September 2026 (Unaudited)	30 June 2026 (Unaudited)	30 September 2025 (Unaudited)	30 September 2026	30 September 2025	31 March 2026 (Audited)
1	**Segment revenue**						
	a) Pharmaceuticals	1,857.59	1,395.79	2,597.06	3,253.38	5,050.23	9,160.45
	b) Printing and packagings	209.96	211.94	113.02	421.90	147.37	486.22
	Total	2,067.55	1,607.73	2,710.08	3,675.28	5,197.61	9,646.67
	Less: Inter segment revenue	57.52	77.96	104.71	135.48	131.87	357.39
	Revenue from operations	2,010.03	1,529.77	2,605.37	3,539.80	5,065.73	9,289.28
2	**Segment results (profit before tax and finance cost from each segment)**						
	a) Pharmaceuticals	-170.93	(273.96)	97.07	(444.89)	155.03	125.72
	b) Printing and packagings	17.25	(47.67)	(217.25)	(30.42)	(342.77)	(584.86)
	Total	(153.68)	(321.63)	(120.18)	(475.31)	(187.74)	(459.14)
	Less: Finance costs	220.89	236.32	201.23	457.21	406.79	841.93
	Loss before tax	(374.57)	(557.95)	(321.41)	(932.52)	(594.53)	(1301.06)

	Particulars	As at 30 September 2026 (Unaudited)	As at 30 September 2025 (Unaudited)	As at 31 March 2026 (Audited)
3	**Segment Assets**			
	a) Pharmaceuticals	19,224.68	22,406.47	18,991.17
	b) Printing and packagings	3,298.34	3,257.06	2,988.27
	Total Segment assets	22,523.02	25,663.53	21,979.44
4	**Segment liabilities**			
	a) Pharmaceuticals	13,364.79	15,278.28	12,457.77
	b) Printing and packagings	3,192.55	2,423.75	2,767.83
	Total Segment liabilities	16,557.34	17,702.03	15,225.60

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT

ANG LIFESCIENCES
INDIA LIMITED

Ref. No. .....

Date.....

Notes:

1. ANG Lifesciences India Limited ('the Company') is a public listed company incorporated in India and is in the business of manufacturing and sales of finished pharmaceutical formulations in a dosage form of Dry Powder Injection Vials, Liquid Injections Vials, Ampoules, PFS, Hard Gelatin Capsules, Tablets, Soft Gelatin Capsules, Dry Syrups, Liquid Syrups and Suspension, Lotions etc. ANG's products portfolio comprises of major therapeutic categories such as Antibiotics, Antiviral, Antimalarial, Antiulcer, Carbapenem, Corticosteroid, Penicillin, Beta Lactamase Inhibitor etc.

2. The above unaudited standalone and consolidated financial results for the quarter and six months ended 30 September 2026 have been reviewed by the Audit Committee and approved by the Company's Board of Directors in their respective meetings held on 14 November 2026. The Statutory Auditors of the Company have expressed unmodified opinion on these results.

3. The above unaudited standalone and consolidated financial results of ANG Lifesciences India Limited ('the Company' or 'the Holding Company') and its subsidiary, Mansa Print and Publishers Limited (the Holding and the subsidiary together referred to as 'the Group') have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as notified by Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act 2013 read with Rule 3 ofthe Companies (Indian Accounting Standard) Rules, 2015, as amended and in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (as amended) and other accounting principles generally accepted in India.

4. These financial results are available on the website of the Company at www.anglifesciences.com and are also available on the website of Bombay Stock Exchange at www.bseindia.com.

5. Previous period figures have been re-grouped/reclassified wherever necessary, to conform to current period's classification.

For and on behalf of the Board of Directors of
ANG Lifesciences India Limited

(Managing Director)

Place: Amritsar
Date: 14 November 2026

KHURANA SHARMA & COMPANY
CHARTERED ACCOUNTANTS
H.No. 1299, SECTOR 15-B, CHANDIGARH
PHONE : 9988070254, 9878029920

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To

The Board of Directors of
ANG Lifesciences India Limited

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results ("the statement") of ANG Lifesciences India Limited ("Holding Company") and its wholly-owned subsidiary (the Holding and its wholly-owned subsidiary together referred to as "the Group"), for the quarter ended 30th September, 2026 attached herewith being submitted by the Holding Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 as amended ("the Listing Regulations") including relevant circulars issued by the SEBI from time to time.

2. This statement which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors has been prepared in accordance with the recognition and measurements principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.

3. We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations. 2015 as amended, to the extent applicable.

4. The Statement includes the result of the following entities:-

Name of the Company	Relation
Mansa Print & Publishers Limited	Indian Subsidiary (wholly owned)

5. Based on our review conducted as per Para 3 above, except for the matters described in the subsequent paragraphs, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. **Emphasis of Matter**

Without modifying our conclusion, we draw attention to the following matter as appearing in the notes to Financial results:

a) According to the information and explanations given to us and based on our examination of the books of account and other relevant records of the Company, the Company has not deposited certain undisputed statutory dues, including dues relating to Employees' State Insurance (ESI), Employees' Provident Fund (EPF), Tax Deducted at Source (TDS) and other applicable statutory dues, with the appropriate authorities within the prescribed due dates. Further, certain outstanding statutory dues have remained unpaid for a period exceeding six months from the dates on which they became payable. The details of such outstanding statutory dues are as follows:

For ANG Lifesciences India Limited:-

Sr. No.	Nature of Statutory Dues	Amount Outstanding (In Lakhs)	Period to which it relates
1.	Employees' State Insurance	₹ 37.15	26-27 - ₹ 6.57 25-26 - ₹ 14.39 24-25 - ₹ 16.19
2.	Employees' Provident Fund	₹ 340.99	26-27 - ₹ 59.53 25-26 - ₹ 145.71 24-25 - ₹ 135.75
3.	Tax Deducted at Source	₹ 60.55	26-27 - ₹ 17.83 25-26 - ₹ 7.60 24-25 - ₹ 35.12
4.	Tax Collected at Source	₹ 0.19	26-27 - ₹ 0.19

	Total	**₹ 438.88**	

For Mansa Print and Publishers Limited:-

Sr. No.	Nature of Statutory Dues	Amount Outstanding (In Lakhs)	Period to which it relates
1.	Employees' State Insurance	₹ 8.59	26-27 - ₹ 1.10 25-26 - ₹ 3.61 24-25 - ₹ 3.88
2.	Employees' Provident Fund	₹ 113.12	26-27 - ₹ 10.34 25-26 - ₹ 23.99 24-25 - ₹ 26.60 23-24- ₹ 30.60 21-22- ₹ 21.59
3.	Tax Deducted at Source	₹ 44.24	26-27 - ₹2.03 25-26 - ₹ 3.65 24-25 - ₹ 12.59 22-23 - ₹25.97
	Total	**₹ 165.95**	

b) According to the information and explanations given to us and based on our examination of the books of account and relevant records of the Company, the following disputed demands raised by the Income Tax Department under the provisions of the Income-tax Act, 1961, are pending as at the reporting date and have not been deposited by the Company. The details of such disputed demands are as follows:

For ANG Lifesciences India Ltd.:

Sr. No.	Period	Nature of Dues	Amount of Disputed Demand (In Lakhs)
1.	2017-18	Direct Tax	₹7.15 (Appeal)
2.	2020-21	Direct Tax	₹ 2.64
	Total		**₹ 9.79**

For Mansa Print & Publisher Ltd:

Sr. No.	Period(AY)	Nature of Dues	Amount of Disputed Demand (In Lakhs)
1.	2012-13	Direct Tax	₹453.95
2.	2010-11	Direct Tax	₹ 14.26
	Total		**₹ 468.21**

c) The Company has availed various credit facilities and borrowings from HDFC Bank, including Cash Credit facilities, Guaranteed Emergency Credit Line (GECL) and Car Loans. However, during the year, the Company has defaulted in the payment of interest and/or repayment of instalments in respect of the aforesaid borrowings. The aggregate outstanding amount of such borrowings as at September 30, 2026. The details of defaults in repayment of principal and interest are as follows:

For ANG Lifesciences India Limited:-

Account Number	Loan Facilities	Sanctioned	Outstanding as on 30-09-2026	Overdue months	Whether Principal or Interest
HDFC Bank cash credit a/c No. 50200055195731.00	Cash Credit	875	163.09	18	INTEREST
HDFC Loan account No. 451760402	GECL	675	325.55	15	PRINCIPAL & INTEREST
HDFC Bank Car Loans	15 Car loans	105.18	2.39	2	PRINCIPAL & INTEREST
HDFC Bank Car loan A/c no. 120026103	Car loan	6.87	3.05	2	PRINCIPAL & INTEREST

For Mansa Print And Publishers limited:-

Account Number	Loan Facilities	Sanctioned	Outstanding as on 30-09-2026	Installment Per month	Overdue months	Overdue amount

HDFC Bank Loan A/c No. 85390052	Term Loan	1000	613.63	15.96	15 month	238.36
HDFC Loan A/c no. 85998201	Term Loan	177.32	125.50	2.79	16 month	44.18
HDFC Bank Loan A/c no. 50200058407747	Cash Credit	500	586.70	Interest Amount	12 month	86.70

The matters referred to in the Emphasis of Matter paragraph indicate the existence of conditions which may affect the Company's liquidity position and require continued monitoring by the management and those charged with governance. Our conclusion is not modified in this respect.

We further state that our reporting is based on the facts and circumstances existing as at the date of the review report. Our reporting should not be construed as an assurance regarding the future viability of the Company nor as a guarantee that the Company will be able to meet all its obligations as and when they fall due within a period of one year from the balance sheet date.

7. **Other Matters**

a) Company was unable to provide the stock statement as on 30 September 2026. Consequently, we are unable to verify the Drawing Power against the Cash Credit facilities.

b) Company was unable to provide certain statements (Current Accounts maintained before takeover from NCLT) required for verification. Accordingly, the scope of our review is restricted to that extent.

For Khurana Sharma & Co.
Chartered Accountants
Firm Registration No. 010920N

CA Vibhor Khurana
Membership No: 568524
Date: 14/11/2026
UDIN: 26568524YSTEYD9579

KHURANA SHARMA & COMPANY
CHARTERED ACCOUNTANTS
H.No. 1299, SECTOR 15-B, CHANDIGARH
PHONE : 9988070254, 9878029920

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To

The Board of Directors of
ANG Lifesciences India Limited

1. We have reviewed the accompanying statement of Unaudited Standalone Financial Results of ANG Lifesciences India Limited ("the Company") for the quarter ended 30th September, 2026 ("the statement") attached herewith being submitted by the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 as amended, including relevant circulars issued by the SEBI from time to time.

2. This Statement which is the responsibility of the Holding Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurements principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as per Para 3 above, except for the matters described in the subsequent paragraphs, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. **Emphasis of Matter**

Without modifying our conclusion, we draw attention to the following matter as appearing in the notes to Financial results:

a) According to the information and explanations given to us and based on our examination of the books of account and other relevant records of the Company, the Company has not deposited certain undisputed statutory dues, including dues relating to Employees' State Insurance (ESI), Employees' Provident Fund (EPF), Tax Deducted at Source (TDS) and other applicable statutory dues, with the appropriate authorities within the prescribed due dates. Further, certain outstanding statutory dues have remained unpaid for a period exceeding six months from the dates on which they became payable. The details of such outstanding statutory dues are as follows:

Sr. No.	Nature of Statutory Dues	Amount Outstanding (In Lakhs)	Period to which it relates
1.	Employees' State Insurance	₹ 37.15	26-27 - ₹ 6.57 25-26 - ₹ 14.39 24-25 - ₹ 16.19
2.	Employees' Provident Fund	₹ 340.99	26-27 - ₹ 59.53 25-26 - ₹ 145.71 24-25 - ₹ 135.75
3.	Tax Deducted at Source	₹ 60.55	26-27 - ₹ 17.83 25-26 - ₹ 7.60 24-25 - ₹ 35.12
4.	Tax Collected at Source	₹ 0.19	26-27 - ₹ 0.19
	Total	**₹ 438.88**	

b) According to the information and explanations given to us and based on our examination of the books of account and relevant records of the Company, the following disputed demands raised by the Income Tax Department under the provisions of the Income-tax Act, 1961, are pending as at the reporting date and have not been deposited by the Company. The details of such disputed demands are as follows:

Sr. No.	Period	Nature of Dues	Amount of Disputed Demand (In Lakhs)
1.	2017-18	Direct Tax	₹7.15
2.	2020-21	Direct Tax	₹ 2.64
	Total		**₹ 9.79**

c) The Company has availed various credit facilities and borrowings from HDFC Bank, including Cash Credit facilities, Guaranteed Emergency Credit Line (GECL) and Car Loans.

However, during the year, the Company has defaulted in the payment of interest and/or repayment of instalments in respect of the aforesaid borrowings. The aggregate outstanding amount of such borrowings as at September 30, 2026, is ₹ 494.08 Lakhs. The details of defaults in repayment of principal and interest are as follows:

Account Number	Loan Facilities	Sanctioned	Outstanding as on 30-09-2026	Overdue months	Whether Principal or Interest
HDFC Bank cash credit a/c No. 50200055195731.00	Cash Credit	875	163.09	18	INTEREST
HDFC Loan account No. 451760402	GECL	675	325.55	15	PRINCIPAL & INTEREST
HDFC Bank Car Loans	15 Car loans	105.18	2.39	2	PRINCIPAL
HDFC Bank Car loan A/c no. 120026103	Car loan	6.87	3.05	2	PRINCIPAL

The matters referred to in the Emphasis of Matter paragraph indicate the existence of conditions which may affect the Company's liquidity position and require continued monitoring by the management and those charged with governance. Our conclusion is not modified in this respect.

We further state that our reporting is based on the facts and circumstances existing as at the date of the review report. Our reporting should not be construed as an assurance regarding the future viability of the Company nor as a guarantee that the Company will be able to meet all its obligations as and when they fall due within a period of one year from the balance sheet date.

6. **Other Matters**

a) Company was unable to provide the stock statement as on 30 September 2026. Consequently, we are unable to verify the Drawing Power against the Cash Credit facilities.

b) Company was unable to provide certain statements (Current Accounts maintained before takeover from NCLT) required for verification. Accordingly, the scope of our review is restricted to that extent.

For Khurana Sharma & Co.
Chartered Accountants
Firm Registration No. 010920N

CA Vibhor Khurana
Membership No: 568524
Date:14/11/2026
UDIN:26568524TJNPCV5963